<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366378</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX 1304</org_study_id>
    <nct_id>NCT01366378</nct_id>
  </id_info>
  <brief_title>Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX</brief_title>
  <official_title>A Phase 1, Open-Label, Study of the Effect of Cimetidine, a Known Inhibitor of Active Renal Secretion, on the Single-Dose Pharmacokinetics of Intravenously-Administered Methylnaltrexone in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals International, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label study assesses the single-dose pharmacokinetics of intravenously-administered
      MNTX in healthy adult male and female subjects in the absence of, and in the presence of,
      orally-administered cimetidine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax) of MNTX prior to and following multi-dose cimetidine regimen</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the potential effects of cimetidine on the pharmacokinetics of MNTX</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration (AUC) of MNTX prior to and following a multi-dose cimetidine regimen</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the potential effects of cimetidine on the pharmacokinetics of MNTX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of MNTX prior to and following a multi-dose cimetidine regimen</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the potential effects of cimetidine on the pharmacokinetics of MNTX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (both total and renal)of MNTX prior to and following a multi-dose cimetidine regimen</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the potential effects of cimetidine on the pharmacokinetics of MNTX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of MNTX prior to and following a multi-dose cimetidine regimen</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the potential effects of cimetidine on the pharmacokinetics of MNTX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subject with adverse events as measured before, during, and after administration of cimetidine</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the potential effects of cimetidine on safety, and tolerability of MNTX</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylnaltrexone (MNTX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylnaltrexone</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males and females between the ages of 18 and 45

          2. Subjects who are non-smokers

          3. Subjects with body weights with range of 154-220 lbs.

        Exclusion Criteria:

          1. Females who are pregnant or lactating

          2. Subjects with a history of any clinically significant disease or condition affecting a
             major organ system

          3. Subjects with ECG abnormalities

          4. Subjects who have tested positive for hepatitis B, hepatitis C or HIV

          5. Subjects who have had a diagnosis of alcohol or substance dependence with the past 12
             months

          6. Subjects with positive urine results for drugs of abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tage Ramakrishna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Progenics Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Progenics Pharmaceuticals, Inc.</name>
      <address>
        <city>Tarrytown</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tage Ramakrishna, MD</name_title>
    <organization>Progenics Pharmaceuticals, Inc</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Cimetidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

